Alzheimer's disease in a dish: promises and challenges of human stem cell models.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Human Molecular Genetics

• Publication date

  2012-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/HMG/DDS319PMID 22865875PMCID PMC3459645
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

  2013cited by this paper
• Alzheimer disease in 2020.

  2012cited by this paper
• Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.

  2012cited by this paper
• Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation.

  2012cited by this paper
• Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells

  2012influential reference
• TALE nucleases: tailored genome engineering made easy.

  2012cited by this paper
• All in the Family: How the APPs Regulate Neurogenesis

  2012cited by this paper
• Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells

  2012cited by this paper
• A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome

  2012influential reference
• Sortilin and SorLA Regulate Neuronal Sorting of Trophic and Dementia-Linked Proteins

  2012cited by this paper
• Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses

  2012cited by this paper
• Axonal transport and neurodegenerative disease: can we see the elephant?

  2012cited by this paper
• Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review

  2012cited by this paper
• CSF biomarkers for Alzheimer's disease: current utility and potential future use.

  2011cited by this paper
• Modeling familial Alzheimer's disease with induced pluripotent stem cells.

  2011cited by this paper
• Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets.

  2011cited by this paper
• Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells

  2011cited by this paper
• Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises.

  2011cited by this paper
• Copy number variation and selection during reprogramming to pluripotency

  2011cited by this paper
• Modelling schizophrenia using human induced pluripotent stem cells

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Alzheimer’s Disease: The Challenge of the Second Century

  2011influential reference
• In brief

  2011cited by this paper
• Autophagy failure in Alzheimer's disease--locating the primary defect.

  2011cited by this paper
• Cell-Surface Marker Signatures for the Isolation of Neural Stem Cells, Glia and Neurons Derived from Human Pluripotent Stem Cells

  2011cited by this paper
• Stem cell technology for neurodegenerative diseases

  2011influential reference
• Alzheimer's disease genetics: lessons to improve disease modelling.

  2011cited by this paper
• O3‐06‐06: The Projected impact of risk factor reduction on Alzheimer's disease prevalence

  2011influential reference
• Genetics of Late-Onset Alzheimer's Disease: Update from the Alzgene Database and Analysis of Shared Pathways

  2011cited by this paper
• Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients

  2011cited by this paper
• Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells

  2011cited by this paper
• Anti-Aβ Drug Screening Platform Using Human iPS Cell-Derived Neurons for the Treatment of Alzheimer's Disease

  2011cited by this paper
• Personalised medicines.

  2011cited by this paper
• Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons.

  2011cited by this paper
• LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.

  2011cited by this paper
• Somatic coding mutations in human induced pluripotent stem cells

  2011cited by this paper
• A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells.

  2010cited by this paper
• Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations.

  2010cited by this paper
• Direct conversion of fibroblasts to functional neurons by defined factors

  2010cited by this paper
• In A Large Clinical Trial, Gamma‐Secretase Inhibitor Tarenflurbil is Found Ineffective for Mild Alzheimer Disease

  2010cited by this paper
• Calcium Channel Blockers Reduce Parkinson Disease Risk

  2010cited by this paper
• Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease

  2009cited by this paper
• Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes

  2009cited by this paper
• Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors.

  2009cited by this paper
• Genetics of Alzheimer's disease: recent advances

  2009cited by this paper
• A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration

  2009cited by this paper
• Variation in the safety of induced pluripotent stem cell lines

  2009cited by this paper
• Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

  2009cited by this paper
• Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

  2009cited by this paper
• Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs

  2009cited by this paper
• Induced pluripotent stem cells from a spinal muscular atrophy patient

  2009cited by this paper
• Evidence for CALM in Directing VAMP2 Trafficking

  2008cited by this paper
• Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects.

  2008cited by this paper
• Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons

  2008cited by this paper
• Zinc-finger Nucleases: The Next Generation Emerges.

  2008cited by this paper
• Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides.

  2008cited by this paper
• Disease-specific induced pluripotent stem cells.

  2008cited by this paper
• When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease.

  2007cited by this paper
• Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease.

  2007cited by this paper
• When loss is gain: reduced presenilin proteolytic function leads to increased Aβ42/Aβ40

  2007cited by this paper
• Insensitivity to Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs and γ-Secretase Inhibitors Is Common among Aggressive Presenilin-1 Mutations*♦

  2007cited by this paper
• Autophagy, amyloidogenesis and Alzheimer disease

  2007cited by this paper
• Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

  2007cited by this paper
• Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.

  2007cited by this paper
• The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism

  2007cited by this paper
• The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease

  2007cited by this paper
• Role of genes and environments for explaining Alzheimer disease.

  2006cited by this paper
• Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.

  2006cited by this paper
• APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

  2006cited by this paper
• CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

  2006cited by this paper
• Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study

  2005cited by this paper
• Cholesterol homeostasis in neurons and glial cells.

  2005cited by this paper
• Presenilin Mutations in Familial Alzheimer Disease and Transgenic Mouse Models Accelerate Neuronal Lysosomal Pathology

  2004cited by this paper
• MAPK recruitment by β‐amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time

  2004cited by this paper
• Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development?

  2004influential reference
• Non‐steroidal anti‐inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action

  2004influential reference
• CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

  2004cited by this paper
• Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3β (GSK3β) plays a critical role in regulating tau's ability to bind and stabilize microtubules

  2003cited by this paper
• CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

  2002cited by this paper
• A γ‐secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish

  2002cited by this paper
• Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Aβ42 production

  2002cited by this paper
• Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease

  2001cited by this paper
• Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila.

  2001cited by this paper
• Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

  2000cited by this paper
• Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

  1996cited by this paper
• Abnormalities of the endosomal-lysosomal system in Alzheimer's disease: relationship to disease pathogenesis.

  1996cited by this paper
• Abnormalities of the Endosomal-Lysomal System in Alzheimer’s disease

  1996cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992cited by this paper

• Microphysiological systems for human aging research

  2024cites this paper
• Direct conversion of urine-derived cells into functional motor neuron-like cells by defined transcription factors

  2024cites this paper
• Mesenchymal Stem Cells and Begacestat Mitigate Amyloid-β 25–35-Induced Cognitive Decline in Rat Dams and Hippocampal Deteriorations in Offspring

  2023cites this paper
• Bone Marrow-Derived Mesenchymal Stem Cells and γ-Secretase Inhibitor Treatments Suppress Amyloid-β25–35-Induced Cognitive Impairment in Rat Dams and Cortical Degeneration in Offspring

  2023cites this paper
• Neuronal hyperexcitability in Alzheimer’s disease: what are the drivers behind this aberrant phenotype?

  2022cites this paper
• How induced pluripotent stem cells changed the research status of polycystic ovary syndrome

  2022cites this paper
• Polymorphic SERPINA3 prolongs oligomeric state of amyloid beta

  2021cites this paper
• Microphysiological Systems for Neurodegenerative Diseases in Central Nervous System

  2020cites this paper
• The Microbiome and the Gut‐Liver‐Brain Axis for Central Nervous System Clinical Pharmacology: Challenges in Specifying and Integrating In Vitro and In Silico Models

  2020cites this paper
• The cellular machinery of post-endocytic APP trafficking in Alzheimer's disease: A future target for therapeutic intervention?

  2020cites this paper
• Important advances in Alzheimer’s disease from the use of induced pluripotent stem cells

  2019cites this paper
• The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model

  2019cites this paper
• Prospects for the application of mesenchymal stem cells in Alzheimer's disease treatment.

  2019cites this paper
• Knowledge domain and emerging trends in Alzheimer’s disease: a scientometric review based on CiteSpace analysis

  2019influential citation
• Induced Pluripotent Stem Cell-Derived Human Glutamatergic Neurons as a Platform for Mechanistic Assessment of Inducible Excitotoxicity in Drug Discovery

  2018cites this paper
• A Human Embryonic Stem Cell Model of Aβ-Dependent Chronic Progressive Neurodegeneration

  2018cites this paper
• Inducible CRISPR genome editing platform in naive human embryonic stem cells reveals JARID2 function in self-renewal

  2018cites this paper
• Endogenous Protein Tagging in Human Induced Pluripotent Stem Cells Using CRISPR/Cas9

  2018cites this paper
• Human Neurospheroid Arrays for In Vitro Studies of Alzheimer’s Disease

  2018cites this paper
• Stem Cell Technology for (Epi)genetic Brain Disorders.

  2017cites this paper
• Systematic gene tagging using CRISPR/Cas9 in human stem cells to illuminate cell organization

  2017cites this paper
• Involvement of the lysosomal protein NPC1 in the pathogenesis of Huntington's disease

  2017cites this paper
• Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities

  2016cites this paper
• “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives

  2016cites this paper
• Imaging organelle transport in primary hippocampal neurons treated with amyloid-β oligomers.

  2016cites this paper
• Promising Therapies for Alzheimer's Disease.

  2016cites this paper
• Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimer’s and Parkinson’s Diseases

  2016cites this paper
• High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress

  2016cites this paper
• Neurotrophin Signaling and Stem Cells—Implications for Neurodegenerative Diseases and Stem Cell Therapy

  2016cites this paper
• Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia

  2015cites this paper
• Ca2+ dysregulation in the endoplasmic reticulum related to Alzheimer's disease: A review on experimental progress and computational modeling

  2015influential citation
• Combating Detrimental Aging-related Uprisings: Impacts of Immunotherapy and Vaccination

  2015cites this paper
• Alzheimer's in 3D culture: Challenges and perspectives

  2015cites this paper
• A 3D human neural cell culture system for modeling Alzheimer's disease

  2015cites this paper
• Low-Level Light in Combination with Metabolic Modulators for Effective Therapy of Injured Brain

  2015cites this paper
• Alzheimer's disease-related amyloid-β induces synaptotoxicity in human iPS cell-derived neurons

  2015cites this paper
• Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development

  2014cites this paper
• Dementia in a dish.

  2014cites this paper
• Stem‐Cell Challenges in the Treatment of Alzheimer's Disease: A Long Way from Bench to Bedside

  2014cites this paper
• Human-induced pluripotent stem cells: potential for neurodegenerative diseases.

  2014cites this paper
• Structure of N-Terminal Sequence Asp-Ala-Glu-Phe-Arg-His-Asp-Ser of Aβ-Peptide with Phospholipase A2 from Venom of Andaman Cobra Sub-Species Naja naja sagittifera at 2.0 Å Resolution

  2014cites this paper
• Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer’s Disease

  2014cites this paper
• Altered Serum Levels of Adipokines and Insulin in Probable Alzheimer's Disease

  2014cites this paper
• Genomic Editing Tools to Model Human Diseases with Isogenic Pluripotent Stem Cells

  2014cites this paper
• Human iPSC Neurons Display Activity-Dependent Neurotransmitter Secretion: Aberrant Catecholamine Levels in Schizophrenia Neurons

  2014cites this paper
• A Commentary on iPS Cells: Potential Applications in Autologous Transplantation, Study of Illnesses and Drug Screening

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

  2014cites this paper
• "Seq-ing" insights into the epigenetics of neuronal gene regulation.

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• Stem cell therapy for Alzheimer's disease: hype or hope?

  2013cites this paper
• Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

  2013cites this paper
• HUMANS, ANIMALS, AND PETRI DISHES: BIOMEDICAL MODELING BETWEEN EXPERIMENTATION AND REPRESENTATION

  2013cites this paper
• Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der

  2012cites this paper